Rezdiffra (Resmetirom) Cost in South Carolina 2026

Note on this draft: this article is pending qualified clinical review. It has been rewritten to separate what is confirmed by FDA and institutional sources from what changes frequently (plan rules, Medicaid formulary status, exact cash prices) and requires direct verification before a patient or clinician relies on it.

Resmetirom is an oral thyroid hormone receptor beta (THR-β) agonist marketed as Rezdiffra. In March 2024, the FDA granted accelerated approval for its use in adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) accompanied by moderate to advanced liver fibrosis (stage F2-F3), as an adjunct to diet and exercise. This approval represents the first and only FDA-cleared indication for this mechanism of action in this patient population. Currently, no generic formulation or FDA-approved biosimilar alternative exists.

The direct answer

Rezdiffra's manufacturer-set list price is in the low thousands of dollars per month, and that list price is national, not South Carolina-specific; a pharmacy in Columbia or Charleston is drawing from the same wholesale price schedule as anywhere else in the country. What actually varies by state and by payer is whether South Carolina Medicaid, a given commercial plan, or a compounding pharmacy will get an individual patient's real out-of-pocket cost far below that list price, and those answers change over time. Any number below the list price depends on insurance tier, prior authorization outcome, manufacturer savings card eligibility, or use of a compounded product, and each of those must be confirmed directly with the payer or pharmacy at the time of fill, not assumed from a published figure.

What is established versus what needs verification

Established (stable, unlikely to change without a new FDA action):

• Rezdiffra is FDA-approved for noncirrhotic MASH with stage F2-F3 fibrosis, based on accelerated approval tied to surrogate liver histology endpoints from its pivotal Phase 3 trial. Continued approval depends on confirmatory trial data.
• The drug is taken once daily by mouth, with dosing based on body weight per the FDA label, and requires liver enzyme monitoring during treatment.
• 503A compounding pharmacies operate under federal FDA compounding rules that require patient-specific prescriptions and FDA-registered API sourcing, in addition to state pharmacy board licensure.

Date-sensitive and payer-specific (must be reverified, not assumed from this article):

• Rezdiffra's exact list price and any published cash-pay price at South Carolina pharmacies.
• Whether South Carolina Medicaid covers resmetirom, under what formulary tier, and what exception process applies. Medicaid preferred drug lists are revised on a rolling basis.
• Which South Carolina commercial insurers cover Rezdiffra, on what tier, and with what prior authorization criteria (specific carrier policies, such as BlueCross BlueShield of South Carolina's exact requirements, are not confirmed in the sources available for this article and should be checked directly with the plan).
• The manufacturer savings card's exact copay floor, annual benefit cap, and eligibility rules, which manufacturers can change.
• Pricing at any specific 503A compounding pharmacy, which varies by supplier and is not standardized.

We have not been able to confirm South Carolina-specific pricing, a specific SC Medicaid coverage determination, or specific commercial payer policy language from a primary source. Where the source material for this article did not support a precise state-level figure, that claim has been removed rather than restated as fact.

Why resmetirom is priced as a specialty drug

Rezdiffra is priced in the range typical of newer specialty hepatology and metabolic drugs, reflecting its status as a first-in-class approval with no direct therapeutic competitor for this exact indication. The FDA's approval was based on the drug meeting dual histologic endpoints in its pivotal trial: a meaningfully higher proportion of resmetirom-treated patients achieved MASH resolution without worsening fibrosis, and fibrosis improvement without worsening MASH, compared with placebo at 52 weeks. Exact percentages and lipid effects reported by the manufacturer and in early trial coverage should be verified against the current FDA label rather than treated as fixed, since labels are updated as more data accumulate.

The FDA-approved prescribing information is the authoritative source for indication, dosing, monitoring requirements, and known adverse reactions: Rezdiffra (resmetirom) prescribing information, FDA. Gastrointestinal side effects, including diarrhea, nausea, and abdominal pain, were among the more commonly reported adverse reactions in the trial population; patients should review the full adverse reaction list in the label with their prescriber rather than rely on secondhand percentages.

South Carolina Medicaid: what we can and cannot say

MASH is closely linked to type 2 diabetes, obesity, and metabolic syndrome, conditions that are common among Medicaid populations nationally (background on chronic liver disease: CDC, Chronic Liver Disease and Cirrhosis). South Carolina has not expanded Medicaid under the Affordable Care Act, which narrows the pool of low-income adults with any Medicaid coverage at all, independent of whether resmetirom specifically is on the formulary.

Whether South Carolina Medicaid currently covers Rezdiffra, and under what prior authorization or step-therapy conditions, is not confirmed by a primary source available for this article and should be checked directly with the South Carolina Department of Health and Human Services or the patient's managed care organization before assuming either coverage or denial. If a Medicaid plan denies coverage, a prescriber-initiated formulary exception request citing the absence of an alternative FDA-approved therapy for MASH-specific fibrosis is a reasonable next step, but approval is not guaranteed and processing times vary by plan.

Commercial insurance, prior authorization, and the savings card

Commercial insurers commonly place newly approved specialty drugs like Rezdiffra on a specialty tier requiring prior authorization, typically involving documentation of fibrosis stage (via biopsy or non-invasive testing), specialist involvement, and a record of lifestyle intervention. The specific criteria used by any given South Carolina commercial plan are set and revised by that insurer and are not something this article can state with confidence; patients should request the plan's current prior authorization policy in writing.

Madrigal Pharmaceuticals offers both a copay reduction program for commercially insured patients and a separate assistance program for those without insurance or with inadequate coverage who satisfy income requirements. Because the manufacturer regularly updates copay thresholds, annual benefit caps, and program eligibility requirements, patients should confirm the most current terms through Madrigal's patient support program rather than relying on stated amounts. Patients enrolled in employer plans incorporating copay accumulator or maximizer mechanisms should confirm directly whether payments made through manufacturer discount cards apply toward their deductible and out-of-pocket limits, as these accumulator designs can substantially reduce or eliminate the discount card's value despite pharmacy acceptance.

Compounded resmetirom: what the tradeoff actually is

Federal law allows 503A compounding pharmacies to prepare a patient-specific compounded version of a drug under specific conditions, including sourcing active pharmaceutical ingredient from an FDA-registered facility and holding valid state pharmacy licensure (FDA, Human Drug Compounding: Compounding Laws and Policies). Compounded resmetirom is generally cheaper than the brand product, which is the main reason patients consider it.

The tradeoff is real and should be stated plainly: compounded drugs are not FDA-approved, do not undergo the bioequivalence testing that generic drugs require, and no published data establish that a compounded resmetirom formulation behaves the same way in the body as the tablet used in the pivotal trial. A patient choosing compounded resmetirom is accepting that uncertainty in exchange for lower cost, not choosing a verified equivalent. Anyone considering this route should confirm the pharmacy's 503A license status with the South Carolina Board of Pharmacy and ask the pharmacy directly about its API sourcing and quality testing.

Telehealth access

Telehealth prescribing of medications like Rezdiffra is broadly permitted for South Carolina-licensed providers evaluating South Carolina residents, which can matter for patients outside the state's larger metro areas where hepatology specialists are concentrated. Telehealth does not remove the need for in-person diagnostic workup: fibrosis staging still requires local lab work (such as a FIB-4 calculation) and imaging or elastography, and ongoing liver enzyme monitoring during treatment still requires periodic blood draws. The exact administrative rules governing telehealth prescribing in South Carolina can change and should be confirmed with the prescribing practice or the South Carolina Department of Labor, Licensing and Regulation if it matters for a specific care plan.

Comparing the realistic cost-reduction paths

Verification checklist before you act on a cost figure

Use this before assuming any specific dollar amount or coverage rule in this space, since insurer, state, and pharmacy facts move faster than a published article can track.

Stable facts you can treat as settled without rechecking today:

• Rezdiffra is FDA-approved (accelerated approval) for noncirrhotic MASH with stage F2-F3 fibrosis.
• It is an oral, once-daily THR-β agonist with no FDA-approved generic.
• 503A compounding is legal under federal law when it meets patient-specific prescription and sourcing requirements.
• Liver enzyme monitoring is part of the FDA-labeled use of this drug.

Facts that require a fresh check dated to the day you check them:

• Current Rezdiffra list price and the cash price quoted by the specific South Carolina pharmacy you plan to use.
• Current South Carolina Medicaid formulary status for resmetirom, confirmed with SCDHHS or the managed care organization directly.
• Your specific commercial plan's prior authorization criteria and specialty tier copay, confirmed with the insurer, not a general summary.
• The manufacturer savings card's current eligibility rules and annual cap, confirmed with the manufacturer's support program.
• Whether your employer plan uses a copay accumulator or maximizer that would offset the savings card benefit.
• The specific compounding pharmacy's current 503A license status with the SC Board of Pharmacy, and its API sourcing.
• Whether any resmetirom clinical trial is currently enrolling near you, checked against a live trial registry rather than a static list.

If you cannot confirm an item on the second list from a primary source dated within the last few weeks, treat any number attached to it as approximate rather than reliable.

When to seek urgent or in-person care rather than relying on telehealth or self-directed cost-shopping

Cost and access decisions should not delay care for warning signs of liver decompensation, including new jaundice, confusion, significant abdominal swelling, vomiting blood, or black tarry stools. These require urgent in-person evaluation regardless of insurance status or where a prescription stands in the prior authorization process.